论文部分内容阅读
一、问题的提出福建归真堂药业股份有限公司是一家注册资本6000万元,成立于2000年的集中药研发、生产、销售为一体的综合性高科技中药制药企业。公司主要从事黑熊养殖及熊胆系列产品的研发、生产和销售。~①2011年起,该企业谋求在中国证券市场创业板上市,遭遇动物保护非政府组织的激烈反对,反对理由主要是归真堂使用活体黑熊取胆汁,手段残忍。~②最终,归真堂撤销了上市申请。2012年,归真堂再次提出上市申请,根据中国证监会公布的《创业板发行监管部首次
First, the issue put forward Fujian Guizhantang Pharmaceutical Co., Ltd. is a registered capital of 60 million yuan, founded in 2000 concentrated drug research and development, production and sales as one integrated high-tech medicine pharmaceutical companies. The company mainly engaged in black bear breeding and bear gall series of product development, production and sales. ~ ① Since 2011, the company has sought to list on the Growth Enterprise Market in China’s securities market and has encountered fierce opposition from animal protection NGOs. The objection is mainly due to Guizhen Church’s use of living bears to take bile, which is cruel. ~ ② Finally, Guizhen Hall revoked the listing application. In 2012, Guizhen Hall once again submitted a listing application, according to the China Securities Regulatory Commission released the "GEM issuance regulatory first